Rituximab, a monoclonal antibody commonly used for lymphoma, targets CD20-positive B cells, and further depletes lymphocyte counts [42–44] while treatments like granulocyte colony-stimulating factor (G-CSF) stimulate neutrophil production [45]. This evidence concerns the gene CSF3 and lymphoma.